Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2597-2605

  Chang, Jose ^a   Couture, Felix ^a   Young, Scott ^a   McWatters, Kara Lee ^a   Lau, Catherine Y ^a  

^a Hotel Dieu de Levis Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BREAST NEOPLASMS; EPOETIN ALFA; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 18444398661     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.027     Document Type: Article

References (20)

1. SEER Web site. Trends in SEER Incidence and US death rates by primary cancer site: 1992-2000. http://seer.cancer.gov/csr/1975_2001
2. Carelle N, Piotto E, Bellanger A, et al: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155-163, 2002
3. Littlewood TJ, Bajetta E, Mortier W: Effects of epoetin alfa on hematologic parameters and QOL in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
4. Ludwig H, Fritz E: Anemia in cancer patients. Semin Oncol 25:2-6, 1998
5. Abels RL: Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 87:4-11, 1992 (suppl 1)
6. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
7. Demetri GD, Gabrilove JL, Blasi MV, et al: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 3:45-51, 2002
8. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and QOL similar to three times weekly dosing. J Clin Oncol 19:2875-2882, 2001
9. Balducci L, Extermann M: Cancer and aging: An evolving panorama. Hematol Oncol Clin North Am 14:1-16, 2000
10. Repetto L, Carreca I, Maraninchi D, et al: Use of growth factors in the elderly patient cancer: A report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 45:123-128, 2003
11. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-AN) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Haematol 34:13-19, 1997
12. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue, and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
13. Demetri GD: Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer 84:31-37, 2001 (suppl)
14. Cleeland CS, Demetri GD, Glaspy J, et al: Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis. Proc Am Soc Clin Oncol 18:574a, 1999 (abstr 2215)
15. Osterborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 20:2486-2494, 2002
16. Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 113:172-179, 2001
17. Crawford J, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895, 2002
18. Demetri GD, Kris M, Wade J, et al: Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumour type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
19. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003
20. Littlewood TJ, Zagari M, Pallister C, et al: Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8:99-107, 2003